FDA recall record

DASH Pharmaceuticals Sucralfate Oral Suspension, USP 1g/10mL recall — FDA D-0749-2022

Labeling: Label Mix-Up

Class IIclassification
D-0749-2022official record ID
Apr 13, 2022report date

Recall record at a glance

Official recordD-0749-2022
CategoryDrug Recalls
ClassificationClass II
FDA record statusTerminated
Recalling firmDASH Pharmaceuticals LLC
Report dateApr 13, 2022
Recall initiation dateMar 11, 2022
Quantity45,940 Unit Dose Cups
LocationUpper Saddle River, NJ, United States

Official product description

Sucralfate Oral Suspension, USP 1g/10mL, packaged in a) 40 case of 10 mL unit Dose Cups (NDC 69339-148-17) and b) 100 case of 10 mL Unit Dose Cups (NDC 69339-148-19) Rx Only, Dash Pharmaceuticals, Upper Saddle River, NJ 07458.

Why the product was recalled

Labeling: Label Mix-Up

Distribution information

Nationwide within the United States

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.